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FREQUENCY OF NEOPLASIA IN 
SYSTEMIC LUPUS ERYTHEMATOSUS 
AND RHEUMATOID ARTHRITIS 
ROBERT B. LEWIS, C. WILLIAM CASTOR, ROBERT E. KNISLEY, and GILES G.  BOLE 
A patient population admitted to the hospital for 
either SLE or RA was surveyed for the subsequent devel- 
opment of neoplasms. The frequency of neoplasm in SLE 
patients appeared to be exaggerated, whereas the fre- 
quency of subsequent neoplasm in rheumatoid patients was 
unexpectedly low. A paucity of nephritis in the SLE group 
was noted. Further reports are encouraged so that the 
magnitude of the risk of  malignancy developing with im- 
munosuppressive therapy can be more precisely ascer- 
tained. 
Laboratory abnormalities suggesting that au- 
toimmune mechanisms are responsible for some of the 
lesions seen with several of the connective tissue diseases 
have led to use of immunosuppressive drugs in the man- 
agement of these disorders. Concern that such agents 
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might impair immunologic “monitoring” of neoplasia 
has been heightened by sporadic reports of neoplastic 
diseases appearing during or following such therapy 
(1-3). I t  is important to determine the natural frequency 
of neoplasia in these diseases in order to assess any 
possible drug-related increases in the frequency of neo- 
plasm developing during the course of any one of the 
connective tissue diseases. 
Recently eight neoplasms were reported in 70 
patients with systemic lupus erythematosus (4). This 
communication reports the experience with neoplasia in 
patients hospitalized with rheumatoid arthritis and sys- 
temic lupus erythematosus in a large teaching hospital 
for the 20-year period, 1955-1974, and focuses on 
patients whose connective tissue disease clearly preceded 
detection of neoplasm. The frequency of neoplasm de- 
veloping in a group of patients with benign essential 
hypertension who were seen in  the same period is re- 
ported as a possible control observation. 
MATERIALS AND METHODS 
The patient populations to be compared were selected 
by computer retrieval of all medical records of hospital admis- 
sions for systemic lupus erythematosus (SLE), discoid lupus 
erythematosus (DLE), rheumatoid arthritis (RA), and benign 
essential hypertension during the period 1955-1974. Patient 
diagnoses are coded by the ICDA and HICDA systems and 
stored in an IBM 370/145 computer using the Mark IV Infor- 
matic’s data retrieval system. Only those hypertensive patients 
were included whose blood pressure abnormality was the 
primary diagnosis at the initial admission. 
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Table 1.  Incidence of New Cancer Cases* 
Hospital New Cancer 
Year Registrations Cases Percent 
1955 48,820 1,705 3.49 
1956 50,073 1,735 3.46 
I957 50.659 1,673 3.30 
1958 49,711 1,574 3.17 
I959 50,609 1,465 2.89 
I960 5 1.947 1,280 2.47 
1961 54,402 1,746 3.22 
I962 56.21 1 1,65 I 2.95 
I963 57,944 1,802 3.12 
1964 60,049 1,835 3.05 
1965 63,086 1,903 3.02 
I966 64,393 1,683 2.62 
1967 65,141 1,681 2.59 
1968 68,280 1.849 2.7 I 
1969 71,771 1,615 2.26 
1970 75,064 1.567 2.08 
1971 76,199 1,815 2.38 
I972 69.3 15 1.742 2.51 
*Reprinted in modified form, with permission of the editors, from 
the report (5) published in the University ofMichigan Medical Center 
Journal, Vol. 41, 1975. 
Patients identified in the four primary disease cate- 
gories were then cross-checked against the tumor registry of 
the University of Michigan Hospital. This registry now in- 
cludes data concerning approximately 62,000 malignant and 
certain benign neoplasms. Recorded data include information 
on the patients’ sex, age, race, age at onset of neoplasm, 
location and histology of neoplasm, extent of disease, type of 
treatment, and length of survival ( 5 ) .  The relative frequency of 
neoplasm in the population visiting the University of Mich- 
igan Hospital over the study period has been approximately 
2-3% of total hospital registrations (Table 1 ). 
Patients with neoplasms included in this study met the 
American Rheumatism Association’s criteria for SLE (6) or 
for definite/classic RA (7). This study attempted to focus on 
those patients with one of the four primary diagnoses who 
developed neoplasms 1 year or more after the primary diag- 
nosis. Thus two records were excluded because the neoplasm 
preceded connective tissue disease, or because the diagnosis of 
both was established within the same year. Nineteen patients 
with other connective tissue diseases or with nonmalignant 
tumors were excluded from the present study. One hundred 
forty-two records from hypertensive patients were rejected 
either because the neoplasm preceded the hypertension or 
because the diagnoses were made at  the same time. The  age, 
sex, and racial characteristics of the four primary diagnostic 
groups a t  the time of initial hospital admission are summa- 
rized in Table 2.  
Although there are problems inherent in a retro- 
spective record review, it is likely that these data may help to 
establish the frequency (period prevalence) of occurrence of 
neoplasia in SLE and RA. Clearly, a study of this nature 
presumes that neoplasms developing in the rheumatic and 
hypertensive patients would be known at the University Hos- 
Table 2. Characteristics of Primary Diagnostic Groups 
Hyper- 
Characteristic tension RA SLE DLE 
Total patients 3.295 2,867 484 253 
Female (%) 49 64 83 68 
Black (Yo) 18 6 14 13 
White(%) 82 94 86 87 
Age (mean f 
SD) 
Female 44.2 f 12.7 46.4 f 17 33.8 f 15.3 39.6 i 14.7 
Male 45.7 f 13.4 47.1 f 18.2 38.3 f 18.4 42.6 f 15.2 
pita1 and included in the tumor registry. Because all hospital 
records are reviewed by a Records Completion Unit, virtually 
all patients are included in the tumor registry if the University 
of Michigan Hospital was involved in the diagnosis, manage- 
ment, or follow-up of their neoplasm. Although one cannot 
exclude the possibility that some rheumatic or hypertensive 
patients may have developed malignancies that were managed 
at  other institutions, some indirect evidence suggests that the 
quality of follow-up of the four primary diagnostic groups is 
comparable. Of patients attending arthritis, hypertension, or 
neoplasm-related clinics during a 6-month period in 1975. 
76%, 88%, and 74%, respectively, came from the adjacent 
twelve-county area in southeastern Michigan. Thus it is clear 
that patients recorded in the tumor registry come largely from 
the same small geographic area from which the rheumatic and 
hypertensive patient populations were drawn. The likelihood 
that rheumatic or hypertensive patients who developed a ma- 
lignancy would be known to the tumor registry is a function of 
the practices and characteristics of the outpatient clinics pro- 
viding follow-up care. Both the arthritis and hypertension 
clinics have had little turnover in senior staff during the period 
Table 3. Types ofNeoplasms Seen in Patients with R A .  DLE.  and SLE 
Neoplasm RA DLE SLE 
Carcinoma of cervix and uterus 
Basal cell carcinoma of skin 
Squamous cell carcinoma of lung 







Squamous cell carcinoma of skin 
Oat cell carcinoma of lung 
H odgk in’s disease 














































17 4 18 
2,867 253 484 
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Table 4. Statistical Summary of*'Period Preoalence" 
I = = R A  = S L E  
0-2 2-4 4-6 6-8 8-10 10-12 12-16 16+ 
DURATION OF RHEUMATIC DISEASE 
AT T I M E  OF CANCER(YRS) 
Fig 1. Duration of rheumatoid arthritis or systemic lupus erythematosus 
in patients who subsequently developed neoplasms. 
1955-1974. Both clinics see 4,000-5,500 outpatients per year, 
over 80% of which are follow-up (return) visits. 
R E S U L T S  
Lupus Erythematosus 
A total of 737 patients were admitted to the 
hospital with the diagnosis of lupus erythematosus dur- 
ing the 20-year review period. Patients with chronic 
discoid lupus (DLE) constituted approximately one- 
third of the group (253 patients) and were considered 
separately. Four neoplasms were found in the DLE 
group (Table 3). A total of 484 patients with SLE were 
at risk. SLE patients with neoplasms had a mean age of 
42.5 years (* SD = 9.8 years; range: 32-63 years). The 
18 SLE patients with neoplasms included 13 females (10 
whites, 3 blacks). The mean time from diagnosis of 
systemic lupus to diagnosis of neoplasm was 7 years, 
with a range of 1-18 years (Figure 1 ) .  
The several types of malignancies found are re- 
corded in Table 3. As noted in Table 4, nearly 4% of this 
particular SLE population ultimately developed some 
kind of malignancy. Table 5 records the frequency of the 
different classification criteria for SLE, and Figure 2 
depicts the frequency distribution of the number of diag- 
nostic criteria detected in individual patients. It is appar- 
ent that most patients had more than the minimum 
criteria (6) required for the diagnosis of SLE. 
Laboratory abnormalities, shown in Table 6, 
Primary Diagnosis Subsequent 
Neoplasms ~ 
No. of Statistical 
Type Patients Number Percent Significance* 
Benign essential hyper- 
tension 3,295 44 1.36 - 
RA 2,867 17 0.59 P < 0.005 
DLE 253 4 1.58 P > 0.70 
SLE 484 18 3.72 P < 0.0005 
* Computed by x z  analysis. 
were those expected with SLE. All patients were treated 
with adrenal corticosteroids, but only 1 received 60 mg 
of prednisone per day or more, and for only I month. 
The other patients generally received 20 mg of predni- 
sone or its equivalent daily, or less. Only 1 patient, a 46- 
year-old woman with thrombocytopenia and hemolytic 
anemia, had been treated with immunosuppressive 
drugs. She had received cyclophosphamide, 100 mg 
daily for 6 days, and 1 year earlier had been treated for 2 
months with 6-mercaptopurine, 50 mg daily. Her last 
exposure to these medications had been 18 months be- 
fore the diagnosis of adenocarcinoma of the lung. 
Rheumatoid Arthritis 
A total of 2,867 patients were admitted to  the 
hospital with the diagnosis of rheumatoid arthritis dur- 
ing the study period. Seventeen neoplasms were found in 
Table 5. Incidence of Criteria for the Classification of SLE in 18 
Patients with Neoplasia 


































* Some patients had more than one abnormality. 
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4 5 6 7 8 9  
NUMBER OF CRITERIA FOR SLE 
Fig 2.  Al l  patients exhibited at least four criteria supporting the diag- 
nosis of sysremic lupus erythematosus. 
this group of patients, an overall “period prevalence” of 
approximately 0.6%. Patient ages ranged from 45 to 79 
with a mean of 61.2 f 8.3 years. Nine patients were 
males, of whom 2 were black, and all 8 females were 
white. At the time of diagnosis of neoplasm, these 
patients had had RA for a mean of 10 years (range: 1-23 
years; see Figure I ) .  The types of malignancies found in 
the RA group are shown in Table 3. Table 7 records the 
clinical characteristics of the patients with RA. Labora- 
tory findings in the RA patients are presented in Table 8. 
There were 2 patients with clinical and laboratory fea- 
tures compatible with Felty’s syndrome. One had a 
melanoma and the other had a basal cell carcinoma of 
the skin and squamous cell carcinoma of the lung. Two 
patients had Sjogren’s syndrome; 1 developed oat cell 
carcinoma of the lung and the other had adenocarci- 
noma of the uterus. Interestingly, 7 of the 17 patients 
with both RA and neoplasm had family members with 
neoplasms, but none was of the same type found in the 
proband. 




Positive LE preparations l 7 o f  I8 94 
Elevated DNA binding 3 o f 9  33 
Decreased complement (CH,,) 2 0 f  10 20 
Positive ANA test l l o f16  69 
Positive latex fixation 2 o f  I6 13 
Criteria Patients Percent 
Morning stiffness 
Soft tissue swelling 
Pain or  tenderness ofjoints 
Symmetric joint swelling 
X-ray abnormalities 
Subcutaneous nodules 





15  88 
14 82 
17 100 
Ten of 17 patients in this group had been treated 
with adrenal corticosteroids, 3 in “bursts” and the other 
7 continuously for 1-20 years. The type of malignancy in 
these patients varied, but three-quarters of the patients 
with basal cell carcinoma had been treated with predni- 
sone. None of the RA patients had received other forms 
of immunosuppressive therapy. 
Benign Essential Hypertension 
Among 3,295 persons admitted to the University 
Hospital primarily for their hypertension during the 
period 1955-1974, 44 (1.36%) subsequently developed 
neoplasms that were recorded in the tumor registry. 
There were 24 female patients with a mean age of 5 1 f 
1 1.3 years and 20 male patients with a mean age of 57.9 
f 9.1 years. 
DISCUSSION 
Studies by Penn, which led to the development of 
an informal tumor registry for renal transplant patients, 
documented an increased incidence of neoplasia i n  
patients treated with immunosuppressive drugs for pro- 
longed periods (3). Leibowitz and Schwartz (2) have 
also suggested that neoplasia can be anticipated as a 
complication of immunosuppressive therapy. It is im- 
portant to determine the baseline frequency of neoplasia 
in association with the connective tissue diseases so that 
the potential increased occurrence of neoplasms in drug- 
treated cases can be recognized. 
Table 8. Laboratory Findings in Patients with RA and Neoplasia 
Lab Finding Patients Percent 
Positive rheumatoid factor 
Positive ANA 
Poor mucin d o t  
Consistent node histology 
Felty’s syndrome 
Sjogren’s syndrome 
17 of 17* I00 
8 o f  10 80 
3 0 f 3  100 
l o f l  100 
3 of I7 18 
2 o f 1 7  12 
* Early tests (1955-1963) were considered positive at any titer. Later 
tests were positive in a titer of at  least 1/640. 
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Ragan and Snyder noted the appearance of can- 
cer in 2% of 374 patients with rheumatoid arthritis fol- 
lowed for 5 years (8). Owens et a1 (9) reviewed 196 
patients with definite or classic RA and found 8 (4.1%) 
who had cancer. The types of tumors were also the same 
as would be expected in the general population. There 
have been several studies of rheumatic populations 
showing an apparent increase in lymphoreticular neo- 
plasms (IO-l7), something not apparent in  the present 
patients or in those reported by Ragan and Owens. 
The neoplasms detected in this study comprise a 
general spectrum of histologic types of malignancy with 
no emphasis on lymphoproliferative disorders. However 
a referral center seeing patients with severe and com- 
plicated diseases may yield data not representative of the 
general population of SLE and RA patients. 
Data from the SLE patients with neoplasms nev- 
ertheless deserve special comment. This group was un- 
usual in that only 1 patient had renal disease. Canoso 
and Cohen noted that 50% of their patients had renal 
disease (4). Although this finding may mean that neph- 
ritis causes death before neoplasia can develop, more 
subtle mechanisms influencing susceptibility to tumor 
development cannot be excluded. Walker and Bole have 
reported an increased occurrence of lymphomas in 
NZB/NZW mice treated with long-term cyclophospha- 
mide to suppress nephritis (18). In  contrast to the RA 
patients, those with SLE developed their neoplasms at a 
younger mean age. 
The sex distribution of SLE patients with neo- 
plasms paralleled the usual sex ratio in this disease. 
However more than half the RA patients with malig- 
nancy were males. The apparent “protection” against 
neoplasia offered by RA (or aspirin?) is interesting. An 
alternative possibility might hold that benign essential 
hypertension, or its treatment modalities, are associated 
with a higher than normal frequency of malignancy. 
Clearly, a control study with a population group simply 
followed for periodic health examinations would be 
valuable. No special clinical characteristics, other than 
the decreased frequency of nephritis in SLE cases, were 
identified in the DLE, SLE, or RA patients that were 
predictive of later development of malignancies. 
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